Rich66
06-21-2009, 12:27 PM
http://www.springerlink.com/content/n5152q702j374751/fulltext.pdf
An interesting introduction to a drug making big waves right now in prostate cancer.
http://www.minnpost.com/healthblog/2009/06/19/9659/mayo_reports_dramatic_outcomes_in_prostate_cancer_ study
There was a stage IV BC trial but I can't find results.
http://clinicaltrials.gov/show/NCT00083278 (http://www.clinicaltrialssearch.org/phase_ii_study_of_mdx010_in_stage_iv_breast_cancer .html)
Anyway..
I found the focus on side effects as early signal of benefit and possibility that traditional measures of efficacy may prematurely deem drugs like this a failure before they gather steam. The paper suggests response rate is almost doubled when given proper length of trial.
More here: http://www.cancerresearch.org/Programs.aspx?id=2340
Yes...me thinks it ties into cancer stem cells and the issues of judging success.
An interesting introduction to a drug making big waves right now in prostate cancer.
http://www.minnpost.com/healthblog/2009/06/19/9659/mayo_reports_dramatic_outcomes_in_prostate_cancer_ study
There was a stage IV BC trial but I can't find results.
http://clinicaltrials.gov/show/NCT00083278 (http://www.clinicaltrialssearch.org/phase_ii_study_of_mdx010_in_stage_iv_breast_cancer .html)
Anyway..
I found the focus on side effects as early signal of benefit and possibility that traditional measures of efficacy may prematurely deem drugs like this a failure before they gather steam. The paper suggests response rate is almost doubled when given proper length of trial.
More here: http://www.cancerresearch.org/Programs.aspx?id=2340
Yes...me thinks it ties into cancer stem cells and the issues of judging success.